Oral administration of recombinant Mycobacterium smegmatis expressing a tripeptide construct derived from endogenous and microbial antigens prevents atherosclerosis in ApoE(-/-) mice.

Vrushali DeshpandeRameshkumar KrishnanSheena PhilipIldiko FaludiThiruvelselvan PonnusamyLakshmi Narasimha Rao ThotaValeria EndreszXinjie LuVijay V KakkarLakshmi A Mundkur

Published in: Cardiovascular therapeutics (2017)

Our results suggest that M. smegmatis can be developed as an oral carrier of recombinant proteins to treat inflammatory autoimmune diseases.

Keyphrases

cell free
mycobacterium tuberculosis
cardiovascular disease
microbial community
cognitive decline
oxidative stress
high fat diet induced
dendritic cells
high fat diet
wild type
mouse model
immune response
adipose tissue
insulin resistance
mild cognitive impairment